EcoR1 Capital’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-10,688,978
| Closed | -$107M | – | 35 |
|
|
2025
Q2 | $107M | Buy |
+10,688,978
| New | +$86.1M | 6.31% | 6 |
|
|
2024
Q4 | – | Sell |
-1,608,616
| Closed | -$16.4M | – | 66 |
|
|
2024
Q3 | $16.4M | Sell |
1,608,616
-1,641,219
| -51% | -$25M | 0.56% | 38 |
|
|
2024
Q2 | $48.2M | Buy |
3,249,835
+1,250,586
| +63% | +$17.9M | 1.48% | 18 |
|
|
2024
Q1 | $27.3M | Buy |
1,999,249
+884,227
| +79% | +$9.63M | 0.69% | 28 |
|
|
2023
Q4 | $12.2M | Buy |
+1,115,022
| New | +$11.1M | 0.32% | 34 |
|
|
2023
Q2 | – | Sell |
-1,300
| Closed | -$17.7K | – | 60 |
|
|
2023
Q1 | $17.7K | Sell |
1,300
-39,180
| -97% | -$702K | ﹤0.01% | 58 |
|
|
2022
Q4 | $791K | Hold |
40,480
| – | – | 0.02% | 60 |
|
|
2022
Q3 | $771K | Sell |
40,480
-239,519
| -86% | -$5.52M | 0.02% | 70 |
|
|
2022
Q2 | $5.77M | Buy |
279,999
+207,178
| +285% | +$4.92M | 0.2% | 46 |
|
|
2022
Q1 | $2.34M | Sell |
72,821
-1,230,336
| -94% | -$44.7M | 0.07% | 61 |
|
|
2021
Q4 | $60.7M | Hold |
1,303,157
| – | – | 1.93% | 15 |
|
|
2021
Q3 | $35.2M | Buy |
1,303,157
+267,293
| +26% | +$6.99M | 1.22% | 16 |
|
|
2021
Q2 | $26.6M | Buy |
1,035,864
+775,864
| +298% | +$18.5M | 0.99% | 20 |
|
|
2021
Q1 | $8.89M | Hold |
260,000
| – | – | 0.39% | 34 |
|
|
2020
Q4 | $8.79M | Hold |
260,000
| – | – | 0.47% | 32 |
|
|
2020
Q3 | $6.41M | Buy |
+260,000
| New | +$6.99M | 0.46% | 28 |
|
Other funds holding ITOS
EcoR1 Capital's ITOS Position: Q3 2025 in Review
EcoR1 Capital sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 10,688,978 shares — an estimated $107M sold.
EcoR1 Capital first reported a position in ITOS in Q3 2020 and held it in 16 quarters. The position peaked at $107M in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- EcoR1 Capital reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- EcoR1 Capital sold 10,688,978 iTeos Therapeutics shares in Q3 2025, an estimated $107M.
- EcoR1 Capital first reported a position in iTeos Therapeutics in Q3 2020 and held it in 16 quarters.
- EcoR1 Capital's iTeos Therapeutics position peaked at $107M in Q2 2025.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on EcoR1 Capital's 13F filing for Q3 2025, filed 14 Nov 2025.